Skip to main
ETNB
ETNB logo

89bio Inc (ETNB) Stock Forecast & Price Target

89bio Inc (ETNB) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 13%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

89bio Inc is positioned favorably within the clinical-stage biopharmaceutical landscape due to its innovative product candidate, pegozafermin, which targets significant unmet medical needs in liver and cardio-metabolic diseases, particularly nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). The company's recent financial reports indicate a solid cash position and prudent spending, allowing for sustained development efforts without immediate dilution risks. Additionally, the promising results from clinical trials for pegozafermin suggest a strong potential market impact, enhancing investor confidence in the company's growth trajectory.

Bears say

89bio Inc faces significant risks that contribute to a negative outlook on its stock performance. Key concerns include the potential failure of its product candidate, pegozafermin, to meet commercial revenue expectations due to limitations in market size, penetration rates, and pricing strategies. Additionally, the company may encounter difficulties securing necessary capital resources to support ongoing operational and developmental initiatives, which poses a further threat to its financial stability and growth prospects.

89bio Inc (ETNB) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 13% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 89bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 89bio Inc (ETNB) Forecast

Analysts have given 89bio Inc (ETNB) a Buy based on their latest research and market trends.

According to 8 analysts, 89bio Inc (ETNB) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

89bio Inc (ETNB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.